Kornimate/medical-research-clean huggingface dataset:
evaluation of vestibular dysfunction or visuospatial perception in individuals with idiopathic scoliosis

Conditions: Scoliosis Idiopathic; Vestibular Function Disorder; Visuospatial/Perceptual Abilities

Summary: this study was planned to investigate whether there is a visual-spatial perception disorder in individuals with idiopathic scoliosis and also to reveal its dependent/independent relationship with vestibular dysfunction.

vestibular dysfunction is thought to be associated with the etiology of patients with idiopathic scoliosis. however, there is limited data on this in the literature. however, visuospatial ability has been evaluated in the literature regarding vestibular dysfunction independent of scoliosis. in the study, it was first requested to investigate vestibular dysfunction in patients with scoliosis. however, as far as is known, there is no study in the literature on visuospatial perception investigated for vestibular dysfunction in patients with scoliosis. this study was planned to investigate whether there is a disorder related to visuospatial perception and to reveal its dependent/independent relationship with vestibular dysfunction. based on the studies, it is planned to evaluate visuospatial (visual-spatial) perception performance in the presence/absence of vestibular dysfunction in individuals with idiopathic scoliosis. the hypothesis of the study is that vestibular function and related visual-spatial perception may be affected in individuals with idiopathic scoliosis.

Eligibility criteria:
inclusion criteria: for the patient and control group; * those who do not have any other joint deformity, * those between the ages of 10-25, * individuals with good mental status only for the experimental group * individuals diagnosed with idiopathic scoliosis, * those who have not received physiotherapy and rehabilitation for idiopathic scoliosis in the last 6 months, exclusion criteria: * those with severe hearing and visual impairment, any neurological, orthopedic, metabolic, rheumatological disorders other than idiopathic scoliosis * other types of scoliosis, * individuals with benign paroxysmal positional vertigo, meniere, primary pathologies of the ear and a history of serious infection (ear, internal organ) will be excluded * in healthy individuals, shoulder height difference during scanning, visual impairment, dizziness in the last 1 year, glasses wearers and individuals with a history of middle ear infection
efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes (sustain - china mrct)

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in africa, asia, europe and south america. the aim of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus sitagliptin 100 mg once-daily on glycaemic control after 30 weeks of treatment. subjects will remain on their stable pre-trial metformin.


Eligibility criteria:
inclusion criteria: - informed consent obtained before any trial-related activities. trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - male or female, age equal to or above 18 years at the time of signing informed consent - subjects diagnosed with type 2 diabetes and on stable treatment in a period of 60 days prior to screening with metformin equal to or above 1500 mg (or maximum tolerated dose equal to or above 1000 mg). stable is defined as unchanged medication and unchanged daily dose - hba1c 7.0 - 10.5 % (53-91 mmol/mol) (both inclusive) exclusion criteria: - female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential not using an adequate contraceptive method throughout the trial including the 5 week follow-up period (adequate contraceptive measure as required by local regulation or practice) - any disorder which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol - treatment with glucose lowering agent(s) other than stated in the inclusion criteria in a period of 60 days before screening. an exception is short-term treatment (equal to or below 7 days in total) with insulin in connection with inter-current illness - history of chronic or idiopathic acute pancreatitis - screening calcitonin value equal to or above 50 ng/l (pg/ml) - personal or family history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia syndrome type 2 (men 2) - impaired renal function defined as estimated glomerular filtration rate (egfr) below 60 ml/min/1.73 m\^2 per modification of diet in renal disease (mdrd) formula (4 variable version) - acute coronary or cerebrovascular event within 90 days before randomisation - heart failure, new york heart association (nyha) class iv
prospective evaluation of the impact on patients' quality of life of a 12-week adapted physical activity program (apa)

Conditions: Sports Physical Therapy

Summary: the objective of this study is to evaluate the effects of regular physical practice on fatigue, quality of life and kinesiophobia in patients treated at the ico in angers, regardless of the type of cancer and the type of treatment.

the objective of this study is to evaluate the effects of regular physical practice on fatigue, quality of life and kinesiophobia in patients treated at the ico in angers, regardless of the type of cancer and the type of treatment. a 12-week adapted physical activity program (apa) is proposed to patients included in the study with an assessment of fatigue, quality of life, level of physical activity and kinesiophobia (fear of movement) at the beginning of the study. a second assessment of fatigue and quality of life will be done during the 6-week management. at the end of the program, a final evaluation of fatigue, quality of life and kinesiophobia will be done.

Eligibility criteria:
inclusion criteria: 1. oncological care at the ico 2. all types of cancer 3. regardless of the type of treatment (chemotherapy, radiotherapy, hormone therapy, immunotherapy) 4. age \> 18 years old 5. follow the apa program at the ico 6. subject informed of the study exclusion criteria: 1. contraindication to the practice of sport 2. apa program outside the ico 3. subject opposing the use of his data 4. minor or adult patient under guardianship or curatorship 5. pregnant woman 6. altered general condition

Keywords: adapted physical activity program (apa) kinesiophobia fatigue quality of life
m-cpp and fenfluramine in cocaine addicts - 3

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to evaluate predictive value of m-cpp and fenfluramine challenges for outcome.


Eligibility criteria:
please contact site for information.

Keywords: cocaine dependence
a 3 months duration interventional study comparing hemodynamic parameters between bolus and fractionated group.

Conditions: Prostatic Hyperplasia, Benign

Summary: the goal of this study is to compare the intraoperative hemodynamic status, characteristics of block of fractionated versus single bolus dose of hyperbaric bupivacaine in patient undergoing transurethral resection of prostate(turp) surgery under subarachnoid block(sab). seventy-two patients aged 50 years and above belonging to american physical status i and ii are divided into two study group. group b will receive injection 0.5 % hyperbaric bupivacaine 2.5 ml single bolus dose and group f will receive same concentration and volume of hyperbaric bupivacaine with two third dose initially (i.e. 1.6 ml) and remaining one third dose (i.e. 0.9 ml) after 60 seconds at the rate of 0.2ml/sec.

the aim of this study is to compare the intraoperative hemodynamic status, characteristics of block of fractionated versus single bolus dose of hyperbaric bupivacaine in patient undergoing turp surgery under sab. seventy-two patients aged 50 years and above belonging to american physical status i and ii undergoing transurethral resection of prostate for benign enlargement of prostate under subarachnoid block are enrolled and are divided into two groups having 36 patients in each. group b will receive injection 0.5 % hyperbaric bupivacaine 2.5 ml single bolus dose and group f will receive same concentration and volume of hyperbaric bupivacaine with two third dose initially (i.e. 1.6 ml) and remaining one third dose (i.e. 0.9 ml) after 60 seconds at the rate of 0.2ml/sec. intraoperative mean arterial pressure (map), heart rate, onset of sensory and motor block, duration of sensory and motor block, and total intraoperative consumption of vasopressor are observed and compared between the groups.

Eligibility criteria:
inclusion criteria: * age: 50 years and above patients undergoing turp surgery under sab * american society of anesthesiologist's physical status: i and ii. exclusion criteria: * patients with history of uncontrolled hypertension. * patients with previous history of cerebrovascular accidents. * patients with history of spinal deformity. * patients with known allergy to local anesthetics. * patient with infection at site of injection. * patient with history of coagulopathy.

Keywords: fractionated dose heavy bupivacaine spinal anesthesia
genetic examination of patients with primary multiple hernia

Conditions: Multiple Hernia

Summary: the investigators are performing a genetic study of patients with multiple hernias (at least 3 primary hernias) versus a healthy control group. this genetic information is compared with circulating and subcutaneously biomarkers such as matrix-metalloproteinases (mmp's). the hypothesis is that patients with multiple hernias have different expression of specific genes compared to the healthy control group.

other examinations performed on the patients enrolled in this study: * ultrasound (us) examination of the abdominal aorta to discover possible abdominal aortic aneurysms. * beightons score to evaluate the degree of joint hypermobility.

Eligibility criteria:
inclusion criteria: * patients with minimum 3 primary hernias exclusion criteria: * patients under 18 years

Keywords: multiple hernia
comparisone of iminoral versus neoral in prevention of acute rejection in renal transplantation

Conditions: End Stage Renal Disease; Renal Transplantation

Summary: cyclosporine is the key drug in organ transplantation. in iran the investigators have more than 2500 new renal transplantation each year and because of this the government pay a huge amount of money for subsiding the imported cyclosporine in the form of neoral. recently an iranian drug company introduced this drug in the name of iminoral which has been approved by different authorities in iran and abroad, (including the ministry of health in iran and also european directorate for the quality of medicines certification unit and fda(department of health and human services,center for drug evaluation and research)). the investigators study is the first clinical trial to compare the effect of iminoral versus neoral in preventing acute rejection in renal transplantation and also to compare the side effects of these two drugs.


Eligibility criteria:
inclusion criteria: 1. renal transplantation candidates 2. written consent 3. not taking participate in any other clinical trial in last 3 months exclusion criteria: 1. primary fsgs 2. hyperoxaluria 3. age under 18 4. multi organ transplantation 5. any malignancy in 5 years 6. pra \> 25% 7. use of tacrolimus 8. hyper acute rejection

Keywords: iminoral neoral acute renal transplant rejection
use of a compliant balloon for large bore catheter navigation in mechanical thrombectomy for stroke: a retrospective study

Conditions: Ischemic Stroke

Summary: the superiority of mechanical thrombectomy (mt) in patients with acute ischemic stroke from large vessel occlusion compared to standard medical therapy alone has been demonstrated by several randomized clinical trials and become the standard of care for these patients. a direct aspiration first pass technique (adapt) for the endovascular treatment of stroke using a large-bore catheter has been reported to be an effective method of achieving mt. recent studies reported that adapt is as efficient and safe as stent retrievers, with a similar successful recanalization rate, but may have better functional outcomes, fewer procedure related-adverse events, and a tendency for faster revascularization compared to the stent-retriever thrombectomy. however, navigation of a large-bore aspiration catheter is not always possible due to unsuccessful passage of the ophthalmic artery origin ("ledge effect") or tortuous vascular anatomy. the coaxial technique comprises guiding the large-bore catheter with a smaller inner catheter and can facilitate distal access. however, there is a gap between the inner catheter and the distal tip of the large-bore outer catheter that creates a risk of damaging the vessel wall and causing dissection or subarachnoid hemorrhage. even with this coaxial technique, it is not always possible to reach the clot site with the large-bore catheter. to decrease the gap between the two catheters, several authors have used, in place of the inner microcatheter, a compliant balloon catheter positioned and inflated at the distal tip of the large-bore catheter. the aim of the present study was to evaluate the safety and efficacy of adapt assisted by a compliant balloon (adapt-ab) when adapt using the coaxial technique fails to reach the clot site.


Eligibility criteria:
inclusion criteria: * endovascular therapy were large arterial occlusions proven by mr angiography, * alberta stroke program early ct score (aspects) \>5 on mri, * baseline national institutes of health stroke scale (nihss) score \>5. if eligible, patients received intravenous thrombolysis (ivt). exclusion criteria: - vertebro-basilar occlusion
evaluation of the prognostic value of preoperative quadriceps and respiratory muscle thickness by ultrasound measurement in cardiac and thoracic surgery patients

Conditions: Cardiac Surgery With Extracorporeal Circulation; Thoracic Surgery

Summary: cardiac and thoracic surgery are major procedures. in order to estimate the operative risk, many scores have been developed, including the euroscore 2 in cardiac surgery. however, the euroscore has limitations since it does not assess all the parameters that may influence postoperative complications, such as the patient's general condition or the status of his or her functional reserves. however, it has been shown that the preoperative functional reserves have a significant impact on the patient's risk of developing postoperative complications following major surgery. in addition, there is a strong association between cardiac failure and a well-described decrease in peripheral muscle lean mass (sarcopenia) in patients older than 65 years. usually, a nutritional assessment is performed during the pre-anesthesia consultation. this assessment is based on clinical and biological criteria that are not totally predictive of the patient's functional reserve status. lean body mass (muscle) is a well-validated marker for the assessment of patients' functional reserves. however, the techniques used to date are complex and require radiation. this study aims to use ultrasound of muscle groups (respiratory muscles - quadriceps muscle - diaphragm) to study the relationship between preoperative muscle mass and postoperative complications in patients over 65 years of age undergoing cardiac or thoracic surgery. this is a prospective observational study to be conducted at the dijon university hospital by the cardiovascular anesthesia-intensive care department. a total of 300 patients will participate in this study, and we have planned to complete the project over a 2-year period. the participating patients (if they do not present any exclusion criteria and are not opposed to inclusion) will be included and undergo a muscle ultrasound in the cardiovascular surgery department or the thoracic and pulmonary surgery department the day before their intervention.


Eligibility criteria:
inclusion criteria: * patient 65 years or older * patients who have not objected to their inclusion in the study * any patient requiring elective cardiac surgery, with extracorporeal circulation extracorporeal circulation or * any patient requiring lung surgery with resection of at least one lobe exclusion criteria: * pneumectomy * person who is not affiliated to national health insurance * person subject to a measure of legal protection (curatorship, guardianship) * pregnant, parturient or breastfeeding women * major unable to express consent * persons with amputations of the proximal segment of a lower limb * persons suffering from a pre-existing neuromuscular pathology, tetra or paraplegia * person who must undergo emergency surgery
safety and pharmacodynamics of gnsc-001 intra-articular injection for knee osteoarthritis

Conditions: Osteoarthritis, Knee; Osteo Arthritis Knee; Knee Osteoarthritis

Summary: the goal of this clinical study is to determine if a single injection of 1 or more dose levels of adeno-associated virus (aav) gene therapy (gnsc-001) is safe and tolerated compared to placebo in participants with painful osteoarthritis (oa) of the knee.


Eligibility criteria:
key inclusion criteria: * oa in at least one knee (the 'target knee'), confirmed using centrally read x-ray with a kellgren-lawrence (kl) score of 2 or 3 * western ontario \& mcmaster university osteoarthritis index (womac) pain score ≥ 20 (on a 50-point numerical rating scale) in the target knee during the seven days prior to screening * persistent moderate to severe symptoms in the target knee, despite failure or intolerance of a 3-month trial of at least 2 conservative therapies (e.g., activity modification, weight loss, physical therapy, opioids, and anti-inflammatory medications, and injection of hyaluronic acid or steroids) * successful extraction of synovial fluid at screening * negative pregnancy test at screening and baseline (subjects of childbearing potential \[socbp\]) key exclusion criteria: * current or documented history of inflammatory arthritis (such as gout or rheumatoid arthritis), inflammation of connective tissue, or other immunological disease * any form of joint degeneration as part of another syndrome (e.g., ehler's danlos, stickler syndrome, etc.) * surgery in the target knee within the 6 months prior to screening * previous partial or total joint replacement in target knee * significant and clinically evident malalignment of the target knee that would impact the subject's function, as determined by the investigator * body mass index (bmi) \> 38 kg/m2 * clinically significant abnormal laboratory values at screening in laboratory parameters that in the opinion of the investigator, could represent a potential risk to participant safety: * plans to have, elective surgery of other joints or spine or intra-articular injections in the target knee, within the next 12 months

Keywords: gene therapy adeno-associated virus intra-articular gnsc-001 genascence knee pain knee arthritis osteoarthritis
the relationship between obesity and chronic headache

Conditions: Traumatic Brain Injury

Summary: the relationship between obesity and the development of chronic headache after traumatic brain injury will be investigated.

traumatic brain injury (tbi) can be defined as an injury caused by an external force, particularly a direct blow to the head or exposure to a shock wave. in addition to the well-known consequences of tbi, including cognitive changes, motor deficits and sensory abnormalities, available evidence suggests that acute and chronic pain is also common after tbi. obesity and tbi can be considered as public health problems with their increasing prevalence in recent years. chronic pain adds to the already enormous clinical, psychological, social and economic burden of obesity. developing mechanisms to prevent the development of pain after tbi has attracted the attention of researchers. obesity is a preventable and modifiable clinical condition. the extent to which obesity may create adverse conditions after tbi remains unclear.

Eligibility criteria:
inclusion criteria: * individuals over the age of 18 who suffered a head injury exclusion criteria: * people with severe head trauma * those who do not speak turkish * those with a history of chronic opioid user * those with alcohol and drug addiction
anti-inflammatory agents and cholesterol metabolism

Conditions: Osteoarthritis

Summary: we hypothesize that administration of anti-inflammatory medications such as celecoxib, naprosyn and diclofenac will cause changes in the blood plasma and white blood cells of patients such that they will be less able to efficiently process cholesterol.

drugs that inhibit cyclooxygenase (cox) are frequently administered to relieve pain and inflammation, but have been associated with cardiovascular (cv) toxicity and an elevated risk of acute myocardial infarction. we have demonstrated that drugs that inhibit the cox-2 isoform act to interfere with cellular cholesterol movement by suppressing expression of proteins that facilitate efflux of cholesterol as well as by enhancing expression of scavenger receptors that mediate cholesterol uptake. we further showed that in cultured thp-1 human macrophages, cox-2 inhibition with drugs (celecoxib, ns398) or by cox-2 rna silencing leads to foam cell transformation, a critical component of atherogenesis. thus, cox-2 inhibitors act in a pro-atherogenic fashion on a series of genes which we have named the "cholesterol metabolic signature." alterations in this signature may contribute to heightened risk of development of atherosclerotic cv disease associated with prolonged use of this drug class. cox enzyme activity supports cholesterol homeostasis through catalysis of prostaglandin (pg) production, and we have shown in vitro that specific subsets of these pgs (pgd2 or pge2) are sufficient to maintain balance. the aims of this project is: in an observational study of persons with pharmacologic cox-2 selective inhibition (celecoxib) or cox-1/2 inhibition (naproxen, diclofenac), document treatment effects on the cholesterol metabolic signature in isolated subject mononuclear cells and in naïve thp-1 monocytes/macrophages exposed to subject plasma. this will allow detection of variations in degree of pro-atherogenic response of the cholesterol metabolic signature to cox inhibition within human patients that may be associated with a higher likelihood of developing cv sequelae. understanding the nature of the association between cox inhibition and cholesterol metabolism, and the extent to which they may promote atherosclerotic cv disease, is of critical importance in developing analgesic and anti-inflammatory medications with a more favorable risk profile. the knowledge gained may also improve clinical decision-making by identifying subsets of patients most vulnerable to adverse cv effects of cox inhibition.

Eligibility criteria:
inclusion criteria: * age 40-70, osteoarthritis, male or female exclusion criteria: * other known autoimmune or inflammatory rheumatic conditions, renal disease, current or recent (\>1 month) corticosteroid or statin treatment, contraindications to medication (i.e. those taking oral anticoagulants, e.g. warfarin), those pregnant or trying to become pregnant or breastfeeding. participants will not have consumed any medications containing aspirin or other nsaids for at least 2 weeks before the trial.

Keywords: atherosclerosis cholesterol cyclooxygenase gene expression lipid metabolism